BeiGene Receives Positive CHMP Opinion for BRUKINSA® (Zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma

BeiGene announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion recommending approval of BRUKINSA® for the treatment of adult patients with marginal zone lymphoma who have received at least one prior anti-CD20-based therapy.
Press Release

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News